Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-asses...
Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
About this item
Full title
Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Therapeutic advances in neurological disorders, 2021-01, Vol.14, p.1756286421990500-1756286421990500
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Alternative Titles
Full title
Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_101d4de7341f4345b19fc307482ff709
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_101d4de7341f4345b19fc307482ff709
Other Identifiers
ISSN
1756-2864,1756-2856
E-ISSN
1756-2864
DOI
10.1177/1756286421990500
